# Histrelin (Supprelin LA / Vantas)

> GnRH agonist implant for central precocious puberty and prostate cancer.

Source: https://peptides.cafe/peptide/histrelin
Category: GnRH Agonist · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
Synthetic nonapeptide GnRH agonist delivered via a subcutaneous hydrogel implant providing continuous release for 12 months, desensitizing the pituitary and suppressing sex steroids.

## Research areas
- Central precocious puberty (Supprelin LA)
- Advanced prostate cancer (Vantas)

## Common research protocols
- Annual implant: 50 mg SC implant in inner upper arm; replaced every 12 months.

## Study summaries
- "Histrelin implant in CPP" — JCEM (2007): Sustained suppression of pubertal progression with single annual implant.

## Considerations
- FDA-approved.
- Implant site reactions and rare implant breakage at removal.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.